Возможности отечественного ингаляционного беклометазона в лечении больных бронхиальной астмой

Summary. Results of efficacy and safety trial of Russian inhaled beclomethasone dipropionate BeclospirR in mild to moderate asthma have been shown in the article. The study involved 60 patients with asthma. During 3 months, clinical efficacy of BeclospirR was compared to that of another preparation of beclomethasone Beclasone Eco using the following common criteria: • clinical symptoms of asthma (patients' dairies); • daily need in short-acting bronchodilators; • peak flow rate; • level of asthma control; • spirometric parameters (FEV1 before and after inhalation of salbutamol); • safety of treatment with BeclospirR. The results demonstrated that BeclospirR was not inferior to Beclasone Eco. Moreover, BeclospirR in the daily dose of 1 000 μg had certain advantages against Beclasone Eco.